

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT AS AT 31 MARCH 2009

**CONDENSED CONSOLIDATED INCOME STATEMENTS
FOR THE QUARTER ENDED 31 MARCH 2009**

	Current Quarter Ended 31.03.2009 (Unaudited) RM'000	Comparative Quarter Ended 31.03.2008 (Unaudited) RM'000	Cumulative Year To Date 31.03.2009 (Unaudited) RM'000	Cumulative Year To Date 31.03.2008 (Unaudited) RM'000
Revenue	6,643	6,153	6,643	6,153
Operating profit	2,005	2,490	2,005	2,490
Operating expenses	(1,657)	(1,351)	(1,657)	(1,351)
Finance costs	(101)	(84)	(101)	(84)
Profit before taxation	247	1,055	247	1,055
Tax expenses	(52)	(123)	(52)	(123)
Profit after taxation	195	932	195	932
Attributable to:				
Ordinary equity share holders of the parent	195	932	195	932
Earnings per share (sen)				
Basic	0.13	0.75	0.13	0.75
Diluted	-	N/A	-	N/A

Notes:-

The condensed consolidated income statements should be read in conjunction with the audited financial statements for the financial year ended 31 December 2008 and the accompanying explanatory notes attached to this interim financial report.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED BALANCE SHEETS
AS AT 31 MARCH 2009**

	As At End Of Current Year Quarter 31.03.2009 (Unaudited) RM'000	As At Financial Year End 31.12.2008 (Audited) RM'000
ASSETS		
Non - current assets		
Property, plant and equipment	9,743	9,363
Product development expenditure	1,267	1,221
Goodwill	58	58
Quoted investment, at cost	11	11
	<u>11,079</u>	<u>10,653</u>
Current assets		
Inventories	11,156	10,712
Trade receivables	7,003	7,398
Other receivables, deposits and prepayments	147	66
Tax refundable	881	1,120
Amount owing by directors	2	-
Fixed deposits with licensed banks	5,191	5,159
Cash and bank balances	4,461	3,828
	<u>28,841</u>	<u>28,283</u>
TOTAL ASSETS	<u>39,920</u>	<u>38,936</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	14,939	14,939
Share Premium	3,520	3,520
Retained profits	14,201	14,006
Merger deficit	(8,397)	(8,397)
	<u>24,263</u>	<u>24,068</u>
Non-current liabilities		
Deferred taxation	424	424
Hire purchase payables	392	392
Term loans	4,180	4,214
	<u>4,996</u>	<u>5,030</u>
Current Liabilities		
Trade payables	4,563	3,699
Other payables and accruals	2,784	2,295
Amount owing to directors	-	166
Hire purchase payables	82	108
Short term borrowings	3,232	3,570
	<u>10,661</u>	<u>9,838</u>
TOTAL LIABILITIES	<u>15,657</u>	<u>14,868</u>
TOTAL EQUITY AND LIABILITIES	<u>39,920</u>	<u>38,936</u>
Net assets per share attributable to ordinary equity holders of the parent (RM)	0.16	0.16

Notes:-

The condensed consolidated balance sheets should be read in conjunction with the audited financial statements for the financial year ended 31 December 2008 and the accompanying explanatory notes attached to this interim financial report.

The net assets per share attributable to ordinary equity holders is calculated based on net asset value and enlarged paid up capital of 149,390,500 shares.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE QUARTER ENDED 31 MARCH 2009**

	← Attributable to Equity Holders of the Company →				Total Equity RM'000
	Share Capital RM'000	Share Premium RM'000	Retained Profits RM'000	Merger Deficit RM'000	
<u>12 months ended 31 December 2008</u>					
<u>(Audited)</u>					
Balance at 1 January 2008	10,398	-	12,111	(8,397)	14,112
Allotment during the financial year:					
- settlement of advances	2,041				2,041
- public issue	2,500	5,500			8,000
Profit for the financial year			1,895		1,895
Listing expenses		(1,980)			(1,980)
Balance at 31 December 2008	<u>14,939</u>	<u>3,520</u>	<u>14,006</u>	<u>(8,397)</u>	<u>24,068</u>
<u>3 months ended 31 March 2009</u>					
<u>(Unaudited)</u>					
Balance at 1 January 2009	14,939	3,520	14,006	(8,397)	24,068
Profit for the year			195		195
Balance at 31 March 2009	<u>14,939</u>	<u>3,520</u>	<u>14,201</u>	<u>(8,397)</u>	<u>24,263</u>

Notes:-

The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2008 and the accompanying explanatory notes attached to this interim financial report.

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD

(Incorporated in Malaysia)

**CONDENSED CONSOLIDATED CASH FLOW STATEMENTS
FOR THE QUARTER ENDED 31 MARCH 2009**

	Current Year To Date Ended 31.03.2009 (Unaudited) RM'000	Corresponding Year To Date Ended 31.03.2008 (Unaudited) RM'000
Cash flows from operating activities		
Profit before taxation	247	1,055
Adjustments for non-cash flow:-		
Depreciation	126	53
Non-cash items	<u>96</u>	<u>66</u>
Operating profit before working capital changes	<u>469</u>	<u>1,174</u>
Changes in working capital		
	<u>969</u>	<u>(733)</u>
	1,438	441
Tax paid	(50)	(146)
Tax refunded	237	520
Interest paid	<u>(93)</u>	<u>(77)</u>
Net cash from operating activities	<u>1,532</u>	<u>738</u>
Investing activities		
Interest received	32	17
Income received from unit trust	-	1
Payment for product development expenditure	(82)	(76)
Purchase of property, plant and equipment	(508)	(28)
Proceeds from disposal of property, plant and equipment	<u>3</u>	<u>-</u>
Net cash for investing activities	<u>(555)</u>	<u>(86)</u>
Financing activities		
Repayment of term loan	(118)	(73)
Repayment to directors	(168)	(38)
Repayment of hire purchase obligation	<u>(26)</u>	<u>(6)</u>
Net cash for financing activities	<u>(312)</u>	<u>(117)</u>
Net decrease in cash and cash equivalents	665	535
Cash and cash equivalents at beginning of the period	<u>8,987</u>	<u>4,458</u>
Cash and cash equivalents at end of the period	<u>9,652</u>	<u>4,993</u>
Cash and cash equivalents comprise:		
Fixed deposits with licensed banks	5,191	2,110
Cash and bank balances	<u>4,461</u>	<u>2,883</u>
	<u>9,652</u>	<u>4,993</u>

Notes:-

The condensed consolidated cash flow statements should be read in conjunction with the audited financial statements for the financial year ended 31 December 2008 and the accompanying explanatory notes attached to this interim financial report.